Phosphatidylinositol (3,4,5)-trisphosphate [PtdIns(3,4,5)P 3 ] is a key regulator of cell signaling that acts by recruiting proteins to the cell membrane, such as at the leading edge during cell migration. Here, we show that PtdIns (3,4,5)P 3 plays a central role in filopodia formation via the binding of myosin-X (Myo10), a potent promoter of filopodia. We found that the second pleckstrin homology domain (Myo10-PH2) of Myo10 specifically binds to PtdIns(3,4,5)P 3 , and that disruption of this binding led to impairment of filopodia and partial re-localization of Myo10 to microtubule-associated Rab7-positive endosomal vesicles. Given that the localization of Myo10 was dynamically restored to filopodia upon reinstatement of PtdIns(3,4,5)P 3 -binding, our results indicate that PtdIns(3,4,5)P 3 binding to the Myo10-PH2 domain is involved in Myo10 trafficking and regulation of filopodia dynamics.
Introduction
Migrating cells display polarized structures such as lamellipodia and filopodia at their leading edge. The formation of lamellipodia requires phosphatidylinositol (3,4,5)-trisphosphate [PtdIns(3,4,5)P 3 ] (Oikawa et al., 2004) , a membrane lipid that localizes to the leading edge of migrating cells in a tightly regulated manner and is linked to actin cytoskeleton remodeling (Chen et al., 2003; Insall and Weiner, 2001; Nishio et al., 2007) . PtdIns(3,4,5)P 3 was also reported to be enriched at the tip of dendritic filopodia (Luikart et al., 2008) . The role of PtdIns(3,4,5)P 3 in cell migration is evident because disruption of PtdIns(3,4,5)P 3 metabolism impairs motility, potentially by inhibiting the specific recruitment of proteins to the leading edge (Nishio et al., 2007) . Conversely, the role of phosphoinositides (PIs) in filopodia formation has remained unclear, although filopodia are functionally involved in cell migration and in important physiological events such as angiogenesis, neuronal growth cone formation and phagocytosis (Cox et al., 2002; Dent et al., 2007; Gerhardt et al., 2003) . PtdIns(3,4,5)P 3 participates in the membrane recruitment of proteins via interaction with PIbinding domains such as pleckstrin homology (PH) domains (Halet, 2005) . Although most PH domains exhibit unspecific binding properties to PIs (Lemmon and Ferguson, 2000) , some are described as being highly specific (Lemmon et al., 1995; Varnai et al., 1999) . For example, PLCd1 and Btk PH domains specifically bind to PtdIns(4,5)P 2 and PtdIns(3,4,5)P 3 , respectively. A few PH domains are also involved in protein-protein interactions (Cohen et al., 2007; Zhu et al., 2007a) . is an actin binding motor possessing three PH domains (Berg et al., 2000) . Myo10 also associates with regions of dynamic actin (Berg et al., 2000) , is recruited to phagocytic cups in a phosphoinositide 3-kinase (PI3K)-dependent manner (Cox et al., 2002) , and plays a role in spindle formation during cell division (Toyoshima and Nishida, 2007; Weber et al., 2004; Woolner et al., 2008) . Myo10 localizes to the tip of filopodia, at least in part owing to its ability to specifically bind bundled actin, and undergoes intrafilopodial motility both towards and from the filopodia tips Kerber et al., 2009; Nagy et al., 2008) . Myo10 also promotes filopodia formation and/or stabilization (Bohil et al., 2006; Zhang et al., 2004) and conveys b-integrins and netrin (Zhang et al., 2004; Zhu et al., 2007b) to the tip of filopodia. However, it remains unclear by which mechanisms Myo10 can promote filopodia. Although dimerization of the Myo10 head, neck and coiled-coil domains has been suggested to be required for Myo10-induced filopodia promotion (Tokuo et al., 2007) , it is still not clear whether the full-length Myo10 protein actually dimerizes (Knight et al., 2005) .
Myo10 contains three distinct PH domains, but the potential specificity of Myo10-PH-domain-binding to PIs and the potential role of PI-binding in Myo10 function are not known in detail. Two recent screenings aiming at isolating PH domains that bind to PI3K products [PtdIns(3,4)P 2 and PtdIns(3,4,5)P 3 ] identified Myo10 as one of the proteins binding to PI3K products, although it was not clear whether Myo10 might bind PtdIns(3,4)P 2 and/or PtdIns(3,4,5)P 3 in these screens (Isakoff et al., 1998; Park et al., 2008) . Here, we show that PtdIns(3,4,5)P 3 plays an important role in filopodia induction via binding to Myo10. We demonstrate that the second PH domain of Myo10 (Myo10-PH2) specifically binds to PtdIns(3,4,5)P 3 and no other PI, although showed no binding to any tested lipids. Upon disruption of Myo10 binding to PtdIns(3,4,5)P 3 , either by mutation of Myo10 or by inhibition of PtdIns(3,4,5)P 3 synthesis, Myo10 partially re-localized from filopodia tips to Rab7-positive vesicles moving along microtubules. Notably, Myo10 localization was reverted from vesicles to filopodia upon restoration of PtdIns(3,4,5)P 3 synthesis, suggesting that PtdIns(3,4,5)P 3 might regulate Myo10 intracellular trafficking. Myo10 binding to PtdIns(3,4,5)P 3 also contributes to Myo10-induced increases in filopodia number. Taken together, these results indicate that PtdIns(3,4,5)P 3 binding regulates Myo10 trafficking and filopodia dynamics.
Results

Myo10 intracellular localization is influenced by its PH domains
The Myo10 domain structure is highly conserved, and includes three PH domains ( Fig. 1A; supplementary material Fig. S1 ). Interestingly, although a construct of mCherry fused to wild-type Myo10 (mCherry-Myo10WT) localized at filopodia tips, deletion of all three Myo10 PH domains caused the partial re-localization of Myo10 to cytosolic puncta (Fig. 1B) . Confocal microscopy showed that these puncta were indeed intracellular and not dorsal or ventral filopodia (Fig. 1B) . This suggests that the PH domains of Myo10 are important in regulating Myo10 localization.
PtdIns(3,4,5)P 3 binds to Myo10-PH2 domain
To determine the lipid-binding capacity of individual Myo10 PH domains, we purified each of the three Myo10 PH domains fused to maltose binding protein (MBP) ( Fig. 2A ; supplementary material Fig. S1 ) and subjected them to a lipid pull-down assay against eight different PIs. MBP-PH2 bound specifically to PtdIns(3,4,5)P 3 , although MBP-PH1, MBP-PH3 and MBP control showed no binding to any of the PIs (Fig. 2B,C) . The Myo10 tail (Myo10Tail), which includes all three PH domains, also bound to PtdIns(3,4,5)P 3 but this binding was lost upon deletion of PH2 (Fig. 2D,E) .
PtdIns(3,4,5)P 3 binding regulates Myo10 localization
Upon observing that Myo10 deleted of its three PH domains was re-localized, we mutated conserved PH domain-residues (which in other PH domains are crucial for lipid binding) in each of the three PH domains of Myo10 ( Fig. 3A ; supplementary material Fig. S1 and Table S1 ). Expression levels of the different constructs were comparable (supplementary material Fig. S2A ). Mutagenesis of the conserved residues in Myo10-PH1 (K1179A) and Myo10-PH3 (K1395A) did not result in altered Myo10 localization (Fig. 3A,B) . However, Myo10-KK1215/6AA (Myo10PH2pm; bearing point mutations in Myo10-PH2) as well as Myo10 with deleted PH2 (Myo10DPH2), showed a similar punctate localization to that observed upon deletion of all three Myo10 PH domains ( Fig. 3B ; supplementary material Movies 1, 2). Coincident with the punctuate staining, Myo10-PH2 mutants were also targeted significantly less to the tips of filopodia (Fig. 3B,C) . Thus, Myo10 localization at the tip of filopodia is regulated by the Myo10-PH2 domain.
We then replaced the Myo10-PH2 domain with wellcharacterized PH domains from Btk, PLCd1 and TAPP1, which bind specifically to PtdIns(3,4,5)P 3 , PtdIns(4,5)P 2 and PtdIns(3,4)P 2 , respectively (Halet, 2005; Varnai and Balla, 2006) (Fig. 3A) . Although replacement of Myo10-PH2 with PtdIns(3,4,5)P 3 -or PtdIns(4,5)P 2 -binding PH domains restored the localization from intracellular puncta to filopodial tips, introduction of a PtdIns(3,4)P 2 -binding PH domain did not correct the mislocalization of Myo10DPH2 (Fig. 3D,E) . This shows that binding to either PtdIns(3,4,5)P 3 or to PtdIns(4,5)P 2 can promote Myo10 localization to the tips of filopodia. 
Complex formation containing more than one Myo10 molecule
We then examined whether different molecules of Myo10 could form complexes. We co-transfected COS-7 cells with either EGFPMyo10WT and mCherry-Myo10WT or with EGFP-Myo10PH2pm and mCherry-Myo10DPH2 (Fig. 4A ) and performed a coimmunoprecipitation with antibodies specific for either EGFP or mCherry (supplementary material Fig. S2B,C) . The full-length Myo10WT co-immunoprecipitated with mCherry-Myo10WT (Fig.  4B, upper panel) . In addition, mutation of the Myo10-PH2 domain had no effect on this association, because the two Myo10-PH2 mutant proteins also co-immunoprecipitated (Fig. 4B, lower panel) . Furthermore, the presence of Myo10WT affected the localization of Myo10DPH2, because mCherry-Myo10DPH2 was localized at tips of filopodia to a higher degree when co-transfected with EGFP-Myo10WT than when co-transfected with EGFP (Fig.  4A,C) . This indicates that different molecules of Myo10 do associate and that Myo10WT can bring the mutant Myo10DPH2 to filopodia tips. Notably, this might explain the detectable though substantially weaker localization of Myo10DPH2 to filopodia tips in singly transfected cells, because endogenous Myo10 is also present in these cells. Thus, the observed localization of Myo10 PH2 mutants in filopodia might result from association with endogenous Myo10 rather than from direct independent targeting.
Inhibition of PI3K reversibly re-localizes Myo10 to cytoplasmic puncta
Given the Myo10 re-localization upon mutation of its PtdIns(3,4,5)P 3 binding site, we next inhibited the production of PtdIns(3,4,5)P 3 using the PI3K inhibitors LY294002 and wortmannin in cells where filopodia were induced by overexpression of Myo10, and analyzed Myo10 localization (Fig.  5A ,C,D; supplementary material Fig. S4 , Movie 3). Efficient PI3K inhibition was controlled by Akt phosphorylation activity (Fig.  5B ). After PI3K inhibition, mCherry-Myo10WT partially relocalized from the tips of filopodia to cytoplasmic puncta, similar to those labeled by mCherry-Myo10DPH2 (Fig. 5A ,C,D). This effect was independent of the mCherry tag because the same effect was seen in cells transfected with EGFP-Myo10WT (supplementary material Movies 4, 5). The effects of the PI3K inhibitors on Myo10 localization were less prominent than those observed with the PH2-mutant forms of Myo10. These differences might arise because filopodia are formed in the presence of the Myo10-PH2 mutant under one experimental condition, although the effects on pre-existing filopodia are characterized in the case of short-term treatment with PI3K inhibitor. Nonetheless, washout of the PI3K inhibitor effectively restored Myo10 filopodial localization (Fig. 5E ), suggesting that the puncta represent a transient re-localization of Myo10 in the absence of PtdIns(3,4,5)P 3 binding.
Myo10 localizes to endosomal vesicles in the absence of PtdIns(3,4,5)P 3 binding
We next performed more detailed analyses of the localization of Myo10-PH2 mutants as well as of Myo10WT in cells treated with PI3K inhibitors. First we noted that the Myo10-PH2 mutants were more soluble in cold Triton than PtdIns(3,4,5)P 3 binding Myo10 (supplementary material Fig. S3 ). Triton insolubility is frequently an indicator of cytoskeletal association (Fox, 1985; Quinn et al., 1989) , and therefore this result suggests that PtdIns(3,4,5)P 3 binding to Myo10WT supports Myo10 binding to F-actin. We also found that the puncta of Myo10-PH2 mutants moved within the cell cytoplasm with top speeds of 0.33±0.05 m/second, ( Fig. 6A ; supplementary material Fig. S4 , Movies 6, 7), which correlates with previously published endosome velocities . This movement was abolished by Nocodazole treatment (Fig. 6A) . These results indicate that in the absence of PtdIns(3,4,5)P 3 binding, Myo10 localizes to vesicles moving along microtubules.
To characterize Myo10-positive vesicles, we co-labeled Myo10-expressing cells with endosomal and lysosomal markers ( Myo10WT increased Myo10 localization to vesicles (Fig. 6B) . In addition, endogenous Myo10 was localized in Rab7-positive vesicles, both in the presence of the PI3K inhibitor LY294002 and to a lower extent in its absence (supplementary material Fig. S5B ). However, endogenous Myo10 was not found in LAMP1-or Rab21-positive vesicles ( Fig. 6B; supplementary material Fig. S5 ) and therefore we cannot exclude the possibility that the observed localization of the mCherry-Myo10-PH2 mutant to lysosomes might be an artifact of protein overexpression. We also found that Myo10 and Rab7 double-positive vesicles undergo dynamic movements close to the cell membrane, as shown by total internal reflection fluorescence microscopy (TIRFM) ( Fig. 6C ; supplementary material Movie 9). This is in line with a previous report describing Rab7 recruitment to clathrin-coated structures at the plasma membrane (Barroso-Gonzalez et al., 2009) . Thus, in the absence of PtdIns(3,4,5)P 3 binding, Myo10 predominantly localizes to endosomal vesicles trafficking close to the plasma membrane, suggesting that Myo10 might be transported to the plasma membrane via Rab7-containing vesicles.
PtdIns(3,4,5)P 3 binding is necessary for Myo10 promotion of filopodia
Myo10 induces filopodia in various mammalian cells Bohil et al., 2006; Zhang et al., 2004) . Because Myo10 defective in PtdIns(3,4,5)P 3 binding was partially relocalized from filopodia, we analyzed whether the binding of PtdIns(3,4,5)P 3 to Myo10 affected its function in filopodia promotion. Although mCherry-Myo10WT, mCherry-Myo10-K1179A (PH1 mutant) and mCherry-Myo10-K1395A (PH3 mutant) transfected cells displayed a large increase in filopodia number in comparison to cells expressing mCherry control, the mCherry-Myo10-KK1215/6AA (PH2 mutant) and mCherryMyo10DPH did not (Fig. 7A,B) . mCherry-Myo10Btk and mCherry-Myo10PLCd1 also promoted filopodia number although mCherry-Myo10DPH2 and mCherry-Myo10TAPP1 failed to induce filopodia (Fig. 7C) . Thus, Myo10 promoted filopodia only when it was able to bind PtdIns(3,4,5)P 3 or PtdIns(4,5)P 2 . In addition, a short treatment with PI3K inhibitor was able to decrease the number of filopodia in mCherry-Myo10WT transfected cells (Fig. 7D) . Expression of mCherry-Myo10WT also caused an increase in filopodia length, although expression of mCherryMyo10DPH2 did not (Fig. 7E ). In conclusion, disruption of Myo10-PtdIns(3,4,5)P 3 binding impaired the capacity of Myo10 to promote filopodia number and length.
Discussion
We demonstrate here that the Myo10-PH2 domain binds specifically to PtdIns(3,4,5)P 3 and that this binding is important for Myo10 localization and function. Myo10 localization to the tip of filopodia is dependent on its head, neck and coiled-coil domains (HMM construct), with the motor domain binding to actin bundles and allowing the protein to reach the tip of filopodia . Myo10 dimerization is also required for the motor domain to get to the tip of filopodia (Tokuo et al., 2007) . These conclusions on the role for the Myo10 HMM region in Myo10 localization are based upon the use of Myo10 constructs lacking the tail (PH, MyTH4 and FERM domains). Although the Myo10 head, neck and coiled-coil domains are sufficient for filopodial tip localization, the full-length Myo10 constructs possessed additional domains that obviously contribute additional localization-regulating properties. Indeed, a construct corresponding to the three PH domains of Myo10 has also been indicated to localize at the plasma membrane (Mashanov et al., 2004) .We therefore conclude that the C-terminal tail of Myo10 also contributes to Myo10 localization by binding to the membrane lipid PtdIns(3,4,5)P 3 .
We demonstrate that different molecules of full-length Myo10 can associate, which is consistent with dimerization of Myo10 (Tokuo et al., 2007) . Myo10 dimerization might be required for its motor activity (Tokuo et al., 2007) . Although Myo10 in solution appears to be mainly monomeric (Knight et al., 2005) , the head domain has been reported to dimerize when two molecules are in close vicinity (Sun et al., 2010) . One hypothesis concerning the regulation of Myo10 dimerization is that Myo10 might dimerize upon cargo binding, just like MyoVI (Yu et al., 2009 ). However, another motor protein, KIF1A, dimerizes only upon binding to PtdIns(4,5)P 2 (Klopfenstein et al., 2002) . Our results are consistent with the dimerization of Myo10 being regulated independently of its PtdIns(3,4,5)P 3 binding.
In addition, we reveal that Myo10, when unable to bind to PtdIns(3,4,5)P 3 , is localized in Rab-7-positive endosomal vesicles. This is consistent with earlier observations of a small amount of Myo10WT being located in intracellular puncta (Berg et al., 2000) . Because we showed that this vesicular localization was reversible (Fig. 5E) , and that the vesicle motion was microtubule-dependent, the endosomal localization of Myo10 might therefore be part of Myo10 trafficking or recycling pathways. The endocytic pathway has recently been described as an assembly platform implicated in actin dynamics and directed cell motility (Gould and LippincottSchwartz, 2009; Palamidessi et al., 2008) . In a similar way, a machinery responsible for filopodia formation might be assembled on Rab-7-positive vesicles and might be activated upon PtdIns(3,4,5)P 3 -Myo10 binding. Rab7 has been shown to be involved in phagocytosis and in phagosome fusion with late endosomes (Harrison et al., 2003) . The formation of filopodia is a key step during phagocytosis, and Myo10 as well as PtdIns(3,4,5)P 3 have been shown to be important in phagocytosis (Cox et al., 2002; Niedergang and Chavrier, 2004 ). An interesting hypothesis is therefore that the Rab7-positive vesicles might be responsible for targeting Myo10 to sites of filopodia and/or phagocytotic cup formation.
We have also demonstrated that Myo10 unable to bind to PtdIns(3,4,5)P 3 was incapable of promoting filopodia, as is HMMMyo10 . The presence of the Myo10 tail is therefore required to increase the number and length of filopodia. Interestingly, a decrease in filopodia number has previously been reported in T cells treated by the PI3K inhibitor wortmannin (Johnson et al., 2008) . In addition, as in our experiments, a recovery in filopodia number was observed after wortmannin washout (Johnson et al., 2008) . Furthermore, inhibition of PI3K by LY294002 reduced filopodial motility in dendritic growth cones (Luikart et al., 2008) . A decrease in filopodia merging rate has also been reported in a melanoma cell line treated with Nocodazole, which suggests that Nocodazole makes filopodia dynamically more stable (Schober et al., 2007) . These reports are consistent with our findings on a role for PI3K in Myo10 trafficking and filopodia dynamics, and a role for microtubules in Myo10-labeled vesicle trafficking. PtdIns(3,4,5)P 3 has been implicated in the regulation of actin polymerization (Chen et al., 2003; Insall and Weiner, 2001) , which is required at the tip of filopodia for their formation. PtdIns(3,4,5)P 3 was also reported to be enriched in dendritic filopodia (Luikart et al., 2008) . The mechanism by which PtdIns(3,4,5)P 3 regulates Myo10 function remains unclear. However, our data support the possibility that PtdIns(3,4,5)P 3 provides an anchor to the membrane (Manna et al., 2008; Oikawa et al., 2004) that recruits Myo10 to the plasma membrane. Thereafter, Myo10 might be involved in transporting PtdIns(3,4,5)P 3 to filopodia tips where it might serve to promote actin polymerization. We also found that Myo10 mutants binding PtdIns(4,5)P 2 were correctly localized and could induce filopodia, suggesting that for filopodia dynamics, binding of PtdIns(3,4,5)P 3 and PtdIns(4,5)P 2 to Myo10 might be exchangeable. Membrane anchoring and actin remodeling are roles that both PtdIns(4,5)P 2 and PtdIns(3,4,5)P 3 can sustain.
We found no binding partners for Myo10-PH1 or Myo10-PH3 domains amongst the PIs tested. PH domains might have other binding targets in addition to PIs, including protein partners (Cohen et al., 2007; Lemmon, 2004; van Rossum et al., 2005; Zhu et al., 2007a) . However, no particular phenotype was seen upon expression of Myo10-PH1 or Myo10-PH3 mutants in mammalian cells. The role of Myo10-PH1 and Myo10-PH3 domains therefore remains unclear. However, Myo10 has several roles in cells; not only is Myo10 implicated in filopodia formation, but also in phagocytosis (Cox et al., 2002) and in cell division (Toyoshima and Nishida, 2007; Weber et al., 2004; Woolner et al., 2008) , and it is possible that PH1 and/or PH3 might have roles in these or other Myo10-driven events.
In conclusion, we have demonstrated that Myo10 binds specifically to PtdIns(3,4,5)P 3 through its second PH domain. Our results also provide new insights into Myo10 trafficking by showing 3531 PtdIns(3,4,5)P 3 regulates myosin-X Images were acquired with a confocal microscope using 0.7m optical slices. In close-ups, regions of interest (ROI) are shown and a pixel line profile is drawn over merged images to illustrate colocalization. Maximum intensity projections are shown. Myo10 in the filopodia tips show no colocalization with Rab7 (yellow arrowheads). (C)Myo10WT is transported close to the plasma membrane in Rab7-positive vesicles. TIRFM imaging shows time-lapse series of COS-7 cells cotransfected with EGFP-Rab7 and mCherry-Myo10WT. Cells were treated with LY294002 to induce the vesicular phenotype of Myo10WT. Three channels were acquired: red shows Myo10 in widefield microscopy, green shows Rab7 in widefield, and blue shows Rab7 in the TIRFM channel (<100 nm proximity to glass surface). An ROI is shown in the panel of images where a vesicle positive for both Myo10 and Rab7 is tracked over time. Vesicle appearance in the TIRFM channel (asterisk) indicates close proximity of the vesicle to the membrane. Scale bars: 10m.
that Myo10 can be localized to endosomal vesicles moving along microtubules. Overall, it is now clear that PtdIns(3,4,5)P 3 binding regulates not only Myo10 localization and trafficking but also the frequency and structure of filopodia.
Materials and Methods
DNA constructs
Myo10-PH2 (E1206-A1304), Myo10-PH3 (E1386-D1491) and Myo10 tail (R1160-R2052) were amplified by PCR (supplementary material Table S1 and Fig. S1 ) and cloned into pMalC2E (New England Bioloabs) within XbaI and HindIII restriction sites to fuse them in N-terminal with MBP. Myo10-PH1 was cloned by deleting PH2 (E1206-A1304) from a Myo10-PH1+PH2 construct (P1170-G1378) (supplementary material Fig. S1 ).
pmCherry-Myo10WT was constructed by substituting EGFP from pEGFP-Myo10 using mCherry amplified by PCR from pR-SETBmCherry (Shaner et al., 2004) . Mutations in these constructs were created using Quickchange XL site-directed mutagenesis kit (Stratagene). Point mutations of Myo10 PH domains (Myo10-K1179A PH1, Myo10-KK1215/6AA PH2 and Myo10-K1395A PH3) were made thanks to primers introducing one or two point mutations into the lipid binding site (supplementary material Table S1 and Fig. S1 ). Primers were also designed to delete the second PH domain of Myo10 (E1206-A1304) while inserting a SpeI restriction site (supplementary material Table S1 and Fig. S1 ). The three PH domains (mCherry-Myo10DPH) were deleted (S1131-Y1472) by adding an AgeI site by sitedirected mutagenesis (see supplementary material Table S1 ) followed by digestion and re-ligation of the construct. Btk, PLCd1 and TAPP1 PH domains were amplified by PCR (supplementary material Table S1 ) and introduced in the mCherryMyo10DPH2 construct in place of PH2, creating three chimeras: mCherryMyo10Btk, mCherry-Myo10PLCd1 and mCherry-Myo10TAPP1. EGFP-Myo10-KK1215/6AA PH2 was constructed by introducing the KK1215/6AA mutations into EGFP-Myo10WT with the same primers as used for pmCherryMyo10-KK1215/6AA PH2.
Plasmids encoding EGFP-Rab4, EGFP-Rab5a, EGFP-Rab7, EGFP-Rab11, EGFP-Rab21 and EGFP-TAPP1PH have been previously described (Barbero et al., 2002; Gomes et al., 2003; Lebrand et al., 2002; Marshall et al., 2002; Pellinen et al., 2006; Rzomp et al., 2003; Wilcke et al., 2000) . Plamids encoding EGFP-BtkPH and EGFP-PLCd1PH were kind gifts from Matthias Wymann (University of Basel, Switzerland). All primers are listed in supplementary material Table S1 . All plasmid sequences were verified by sequencing prior to use. Nucleotide alignment shown in supplementary material Fig. S1 was performed using Clustal W and Clustral X (Larkin et al., 2007) .
Cell culture and transfection
HeLa carcinoma cells were cultured in Dulbecco's modified Eagle's medium (DMEM) (Invitrogen) with 5% FBS. COS-7 African green monkey kidney cells and MDA-MB-231 breast adenocarcinoma cells were cultured in DMEM with 10% FBS. Mouse aortic endothelial (MAE) cells were cultured in RPMI (Invitrogen) with 10% FBS. All DNA constructs were transfected using Lipofectamine 2000 (Invitrogen) or Fugene6 (Roche) according to the manufacturer's protocol.
Antibodies and reagents
The following antibodies and dyes were used: anti-RFP (PM005, MBL), anti--tubulin (12G10, Developmental Studies Hybridoma Bank, Iowa), anti-actin (JLA20, Developmental Studies Hybridoma Bank, Iowa), anti-LAMP1 (Santa Cruz Biotechnology), MBP-Probe (N17, Santa Cruz Biotechnology), anti-GFP (Clontech), anti-Akt (Cell Signaling), anti-phospho-Akt (Ser473) (Cell Signaling), anti-Myo10 (2243.00.02, SDIX) and anti-Rab7 (Rab7-117, Abcam), rabbit IgG (Sigma), FITCPhalloidin (Invitrogen), Hoechst 33342 (Sigma). Alexa-Fluor-680 and Alexa-Fluor-700 secondary antibodies (Invitrogen) were used in LI-COR's Odyssey Infrared Imaging System and horse radish peroxidase-conjugated secondary antibodies (Jackson ImmunoResearch Laboratories) were used for detection by chemiluminescence. Nocodazole (10 M, 1 hour at 37°C) was used to depolymerize microtubules. LY294002 (Sigma) (10-20 M, 1 hour at 37°C) and wortmannin (Sigma) (0.15 M, 1 hour at 37°C) were used to inhibit PI3K.
Protein purification and lipid pull-down assay
Proteins were produced with pMalC2E constructs. Plasmid expression was induced by IPTG and the bacteria were grown for 1 hour at 37°C prior to lysis. The proteins were then purified on an Amylose column (New England Biolabs) in accordance with the manufacturer's protocol.
Lipid pull-down assay was performed with PIP beads (Echelon Biosciences) according to the manufacturer's protocol. Briefly, 25 l of PIP bead slurry at 10 nM was incubated with 0.04 g/l of purified Myo10 PH domains for 3 hours at 4°C, and then washed in 10 mM HEPES pH 7.4, 150 mM NaCl and 0.25% NP-40. Proteins bound to the beads were eluted in SDS-sample buffer and resolved by SDS-PAGE. Immunoblotting was analyzed with a VersaDoc Imaging System (Bio-Rad). Binding, defined as the ratio between the intensity of the bound fraction and the intensity of the input, was calculated.
Microscopy techniques
For imaging of fixed cells, cells were plated on Ibitreat -Dish dishes (Integrrated Biodiagnostics) one day before transfection. Transfected cells were fixed 12-24 hours after transfection with 2% paraformaldehyde, permeabilized with Triton-X100 and blocked with 2% BSA/PBS. Alternatively, cells were replated 24 hours after transfection on glass coverslips and allowed to attach for 2 hours prior to fixation.
Primary antibodies were used with predetermined optimal concentrations of 5-10 g/ml. The concentration of Alexa-Fluor-conjugated secondary antibodies (Invitrogen) was 5 g/ml. Alexa-Fluor-conjugated and FITC-conjugated phalloidins (Invitrogen) were used for F-actin detection. Cells were imaged on an Olympus IX71 microscope with Olympus 63ϫ oil/1.4NA objective and a CCD Hamamatsu camera.
In (E)PtdIns(3,4,5)P 3 binding is necessary for Myo10-induced increase in filopodia length. Filopodia length was measured in COS-7 cells expressing mCherry, mCherry-Myo10WT or mCherry-Myo10DPH2. Bar graph displays the proportion of filopodia shorter than 1.5m, between 1.5m and 2.5m, or longer than 2.5m, based on seven independent experiments. Graphs display means + s.e.m. Comparison by Student's t-test (ns, not significant; *P<0.05, **P<0.01, ***P<0.001) to the mCherry-control as indicated on top of the bars or as indicated by brackets.
hours after transfection. To maintain optimal conditions, a cell culture dish heater, objective heater at 37°C and 4.8% CO 2 support were used. Confocal threedimensional images were taken using Zeiss Axiovert 200M with spinning disc confocal unit Yokogawa CSU22 and Zeiss Plan-Neofluar 63ϫ oil/1.4 NA objective. Z-stacks with 1 airy unit (approx. 0.7 m) optical slices were acquired with a step size of 0.3-0.7 m between slices.
In TIRFM, cells were plated as above on Mattek glass bottom dishes. An Olympus IX71 MT20 CellR system with 60ϫ oil/1.45NA TIRFM objective, MWB2 TIRF/FITC filter block and a 488 nm laser line was used to acquire total internal reflection images and widefield epifluorescence images sequentially (University of Turku, Department of Cell Biology and Anatomy). The maximum intensity projections were created with SlideBook 4.2.0.7 software and NIH ImageJ. QuickTime movies from time-lapse experiments were created using NIH ImageJ software.
In live-cell experiments, transfected cells were imaged 12-24 hours after transfection. Confocal three-dimensional images were taken using Zeiss Axiovert 200M. For PtdIns(3,4,5)P 3 localization experiments, cells were imaged with a Zeiss LSM 510.
Image analysis
ImageJ plugin Particle Detector and Tracker (Sbalzarini and Koumoutsakos, 2005) was used to automatically detect, track and visualize vesicle trajectories in timelapse movies. Also, manual tracking and plugin MTrackJ (Erik Meijering, University Medical Center, Rotterdam, The Netherlands) were used in tracking vesicles. Cell Counter (Kurt De Vos, University of Sheffield, Sheffield, UK) and Manual Tracking (Fabrice P. Cordelières, Institut Curie, Orsay, France) plugins were used to count filopodia and track cells, respectively. Standard ImageJ tools were used to draw line profiles and measure filopodia length as well as signal intensities. Quantitative analysis of colocalization was done with the help of ImageJ plugin JACoP (Bolte and Cordelieres, 2006) . Costes' approach was used to calculate Pearson correlation coefficients in the whole cell level for endogenous Myo10, Rab7 and Rab21 (Costes et al., 2004) .
Cold Triton fractionation
Cold Triton fractionation protocol was modified from a published method (Ding et al., 1996) . Transfected COS-7 cells were washed and scraped in ice-cold cytoskeletonstabilizing buffer (CSK buffer) containing: 250 mM sucrose, 3 mM MgCl2, 150 mM KCl, 1 mM EGTA and 1 mM PMSF in 10 mM PIPES, pH 6.8. After spinning-down at 7000 g for 5minutes at +4°C, the pellet was resuspended in ice-cold 0.2% Triton X-100 (Sigma) in CSK buffer with protease inhibitor cocktail (Complete, Roche) and incubated on ice for 20 minutes. After centrifugation at 15,000 g for 10 minutes, the supernatant was considered as a soluble fraction and the pellet was considered as an non-soluble fraction. Supernatant and pellet were analyzed with standard western blotting techniques and detected using the LI-COR Odyssey Infrared Imaging System. The protein load was balanced to the tubulin signal.
Co-immunoprecipitation
At 24 hours after transfection, cell lysates were prepared in RIPA buffer from COS-7 cells co-transfected either with EGFP-Myo10WT and mcherry-Myo10WT or with EGFP-Myo10-KK1215/6AA PH2 and mCherry-Myo10DPH2. Cell lysates were incubated in the presence of anti-GFP antibody. Protein G beads (Santa Cruz Biotechnology) were used to capture the beads to which the antibodies and proteins were bound. Samples extracts were resolved by SDS-PAGE and detected by immunoblotting with an anti-RFP antibody (MBL, Japan).
